â– LECTURE OVERVIEW: Neonatal Jaundice (hyperbilirubinemia) is a common clinical finding, classified chronologically into physiological and pathological profiles.
â– THE DYNAMIC SPLITS:
1. Physiological Jaundice (Normal/Benign):
- Pathogenesis: Caused by a transient, relative deficiency of hepatic UDP-glucuronosyltransferase (UGT) activity in a neonate with high red cell turnover.
- Timeline: Arises after the first 24 hours of life, peaking on days 3-5 before resolving.
2. Pathological Jaundice (Diseased):
- Pathogenesis: Driven by hemolysis (e.g., Rh/ABO incompatibility), biliary atresia, or sepsis.
- Timeline: Begins within the first 24 hours of life. Bilirubin levels rise quickly (>5 mg/dL/day or >15 mg/dL total).
â– IMMUNOLOGICAL & CYTOKINE SIGNALLING FLUX:
Pathogen exposure or cellular distress triggers antigen-presenting cell activation. This results in the release of pro-inflammatory cytokines (such as IL-1, TNF-alpha, and IL-6) and triggers receptor-mediated cellular chemotaxis.
â– ACUTE TOXICOLOGICAL PROFILE:
High cumulative chemical exposure or accidental overdose triggers systemic receptor overload, cellular injury, and metabolic acidosis.
[HY-BOARD-1176]
🌟 Dynamic Clinical Key:
In pathological jaundice, high levels of unconjugated (indirect) bilirubin can cross the blood-brain barrier. Bilirubin deposits selectively in the basal ganglia, predisposing the neonate to acute bilirubin encephalopathy or permanent, devastating Kernicterus. Target specific monoclonal antibodies or immune suppressors to control the hyper-inflammatory cascade. Immediate administration of physiological charcoal or specific receptor antagonists is lifesaving.